These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1069 related items for PubMed ID: 20590741

  • 1. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
    Scheen AJ.
    Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
    [Abstract] [Full Text] [Related]

  • 2. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
    Scheen AJ.
    Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
    [Abstract] [Full Text] [Related]

  • 3. DPP-4 inhibitors and their potential role in the management of type 2 diabetes.
    Barnett A.
    Int J Clin Pract; 2006 Nov; 60(11):1454-70. PubMed ID: 17073841
    [Abstract] [Full Text] [Related]

  • 4. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
    He YL.
    Clin Pharmacokinet; 2012 Mar 01; 51(3):147-62. PubMed ID: 22339447
    [Abstract] [Full Text] [Related]

  • 5. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
    Scheen AJ.
    Postgrad Med; 2013 May 01; 125(3):7-20. PubMed ID: 23748503
    [Abstract] [Full Text] [Related]

  • 6. Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions.
    Prescrire Int; 2011 Feb 01; 20(113):33-7. PubMed ID: 21488586
    [Abstract] [Full Text] [Related]

  • 7. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Deacon CF, Holst JJ.
    Adv Ther; 2009 May 01; 26(5):488-99. PubMed ID: 19444391
    [Abstract] [Full Text] [Related]

  • 8. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
    Langley AK, Suffoletta TJ, Jennings HR.
    Pharmacotherapy; 2007 Aug 01; 27(8):1163-80. PubMed ID: 17655515
    [Abstract] [Full Text] [Related]

  • 9. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
    Scheen AJ.
    Diabetes Metab; 2012 Apr 01; 38(2):89-101. PubMed ID: 22197148
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA.
    Clin Ther; 2006 Jan 01; 28(1):55-72. PubMed ID: 16490580
    [Abstract] [Full Text] [Related]

  • 11. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Gallwitz B.
    IDrugs; 2008 Dec 01; 11(12):906-17. PubMed ID: 19051153
    [Abstract] [Full Text] [Related]

  • 12. Role of vildagliptin in managing type 2 diabetes mellitus in the elderly.
    Halimi S, Raccah D, Schweizer A, Dejager S.
    Curr Med Res Opin; 2010 Jul 01; 26(7):1647-56. PubMed ID: 20441397
    [Abstract] [Full Text] [Related]

  • 13. [Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].
    Matthes J, Faust M.
    Dtsch Med Wochenschr; 2008 Oct 01; 133(43):2233-7. PubMed ID: 18924057
    [No Abstract] [Full Text] [Related]

  • 14. Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor.
    Boulton DW.
    Clin Pharmacokinet; 2017 Jan 01; 56(1):11-24. PubMed ID: 27282159
    [Abstract] [Full Text] [Related]

  • 15. The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
    Filippatos TD, Athyros VG, Elisaf MS.
    Expert Opin Drug Metab Toxicol; 2014 Jun 01; 10(6):787-812. PubMed ID: 24746233
    [Abstract] [Full Text] [Related]

  • 16. The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond.
    Panina G.
    Diabetes Obes Metab; 2007 Sep 01; 9 Suppl 1():32-9. PubMed ID: 17877545
    [Abstract] [Full Text] [Related]

  • 17. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.
    Golightly LK, Drayna CC, McDermott MT.
    Clin Pharmacokinet; 2012 Aug 01; 51(8):501-14. PubMed ID: 22686547
    [Abstract] [Full Text] [Related]

  • 18. Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
    Charbonnel B, Schweizer A, Dejager S.
    Hosp Pract (1995); 2013 Apr 01; 41(2):93-107. PubMed ID: 23680741
    [Abstract] [Full Text] [Related]

  • 19. Incretin-based therapies in type 2 diabetes: a review of clinical results.
    Bosi E, Lucotti P, Setola E, Monti L, Piatti PM.
    Diabetes Res Clin Pract; 2008 Dec 15; 82 Suppl 2():S102-7. PubMed ID: 19022515
    [Abstract] [Full Text] [Related]

  • 20. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin.
    Ahrén B, Foley JE, Bosi E.
    Diabetes Obes Metab; 2011 Mar 15; 13(3):193-203. PubMed ID: 21205107
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.